Developer docs
API playgroundTry for free, no card

Search company profiles

Surrozen

Full company profile

uuid0000xwl

Namestring
Surrozen
Legal namestring
Surrozen, Inc.
Websiteurl
surrozen.com
Company typeenum
Public
Founded yearint
2016
Descriptiontext

Surrozen is a clinical-stage biopharmaceutical company developing antibody therapeutics that selectively activate the Wnt signaling pathway to drive tissue repair and vascular regeneration in the eye. Founded in 2016 in South San Francisco and publicly listed on Nasdaq under ticker SRZN, the company operates with 11-50 employees and is led by CEO Craig Parker. Its proprietary SWAP (Surrozen Wnt Signal Activating Proteins) platform engineers multivalent antibodies capable of combining Wnt pathway activation with modulation of other disease drivers such as VEGF and IL-6, addressing ophthalmic indications with high unmet need including wet age-related macular degeneration, diabetic macular edema, and uveitic macular edema.

The pipeline comprises SZN-413 (a FZD4-targeting bispecific Wnt agonist licensed to Boehringer Ingelheim, with a milestone achieved in 2025), SZN-8141 (a FZD4/VEGF bifunctional antibody with IND filing expected in H2 2026), SZN-8143 (a FZD4/VEGF/IL-6 trifunctional antibody with IND expected in 2027), and SZN-113 (a multi-Wnt-receptor agonist for corneal and retinal degenerative conditions). The company discontinued its SZN-043 liver disease candidate in March 2025 to focus exclusively on ophthalmology.

The business model is a hybrid of out-licensing (SZN-413 to Boehringer Ingelheim) and future direct commercialization of wholly-owned ophthalmology assets. With no commercial products today, Surrozen generates de minimis collaboration revenue (Q4 2025: $0.53M) and is funded by a $175M oversubscribed private placement completed in March 2025, alongside public equity capital. Target customers are ultimately retinal specialists and their patients, with the company signaling a traditional biotech GTM of clinical development, analyst/investor engagement, and strategic licensing partnerships rather than direct sales infrastructure.

Short descriptiontext

Surrozen is a clinical-stage biopharmaceutical company that engineers multivalent antibodies to selectively activate Wnt signaling for the treatment of retinal vascular diseases, with a pipeline of drug candidates for wet AMD, diabetic macular edema, and uveitic macular edema.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
Wnt pathway therapeutics, ophthalmic antibody therapeutics, retinal disease pipeline, biopharmaceutical drug development, multifunctional antibody engineering
Industry1 code
PRIMARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Ophthalmic Biopharmaceutical Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Revenue
TypeOne Time License
Description

Surrozen is a clinical-stage biopharmaceutical company with no current product revenue. The company is developing drug candidates targeting ophthalmic diseases and plans to commercialize pipeline assets upon regulatory approval. Future revenue will come from product sales, likely through licensing agreements or direct commercialization.

biospace.com
2Licensing and Collaboration Revenue
TypeLicensing Royalties
Description

The company has licensing arrangements such as the Boehringer Ingelheim collaboration for SZN-413, which may generate milestone payments and potential royalties. The March 2025 $175M private placement discontinuing liver disease candidate SZN-043 indicates strategic focus on ophthalmology programs with potential partnership revenue.

biospace.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1SWAPs (Surrozen Wnt Signal Activating Proteins)
Description

Proprietary multivalent antibodies that potently and selectively activate Wnt signaling in ocular tissues

surrozen.com
Core offering1 text field

Surrozen is a clinical-stage biopharmaceutical company that develops multifunctional antibody therapeutics targeting the Wnt signaling pathway for ophthalmic diseases. Using its proprietary SWAP platform, Surrozen engineers multivalent antibodies that selectively activate Wnt signaling in ocular tissues to treat retinal vascular diseases including wet AMD, diabetic macular edema, and uveitic macular edema. The pipeline includes SZN-413 (licensed to Boehringer Ingelheim), SZN-8141, SZN-8143, and SZN-113.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • SZN-8141 peak probability-adjusted net sales projected at $895 million for diabetic macular edema and $614 million for neovascular age-related macular degeneration
+2 more records
Product overview1 text field

Surrozen is a clinical-stage biotechnology company that has developed a proprietary antibody-engineering platform to discover multifunctional antibodies targeting ophthalmic diseases. The company's pipeline includes multiple drug candidates: SZN-413 (FZD4 agonist, licensed to Boehringer Ingelheim), SZN-8141 (FZD4 + VEGF bifunctional antibody for wet AMD and DME), SZN-8143 (trifunctional antibody targeting FZD4, VEGF, and IL-6), and SZN-113 (agonist for FZD1, FZD2, FZD7 receptors). The underlying technology platform, SWAP (Surrozen Wnt Signal Activating Proteins), enables multivalent antibodies that potently and selectively activate Wnt signaling for tissue repair and regeneration.

Product and service1 record
1SZN-413
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Boehringer Ingelheim
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Strategic collaboration with Boehringer Ingelheim for SZN-413, a targeted bispecific Wnt agonist antibody for the treatment of retinal vascular diseases such as wet AMD and DME. Boehringer Ingelheim has licensed SZN-413 from Surrozen and is responsible for further development and potential commercialization. A milestone achievement by Boehringer Ingelheim for SZN-413 was reported in 2025.

biospace.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing novel therapeutics for retinal vascular diseases including wet AMD and DME. Directly comparable as a small-cap ophthalmology biotech pursuing next-generation alternatives to anti-VEGF therapy with a pipeline of biologic candidates.

TypeDirect peer
Description

Clinical-stage gene therapy company focused on wet AMD and diabetic retinopathy. Directly comparable as a small-cap ophthalmology biotech developing novel mechanism therapies for retinal vascular disease.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing therapies for retinal diseases and other ophthalmic conditions including wet AMD. Comparable as a public ophthalmology-focused biotech with multiple pipeline assets in retinal disease.

TypeDirect peer
Description

Commercial-stage biopharmaceutical company with Syfovre and Empaveli for ophthalmology indications including geographic atrophy. Directly comparable as an ophthalmology-focused biotech, though more advanced commercially.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing ONS-5010/LYTENAVA, a candidate treatment for wet AMD. Directly comparable as a small ophthalmology-focused biotech targeting the wet AMD market.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing complement-mediated therapies for ophthalmology (geographic atrophy) and neurology. Comparable as a clinical-stage biotech with novel mechanism ophthalmology programs.

TypeEmerging player
Description

Clinical-stage gene therapy company with ABBV-RGX-314 for wet AMD in collaboration with AbbVie. Comparable for its ophthalmology pipeline and partnership-driven business model, though using a different modality (gene therapy).

TypeEmerging player
Description

Clinical-stage cell therapy company with OPC1 for retinal indications. Comparable as a small-cap biotech developing novel regenerative therapies for ophthalmology, with a different modality (cell therapy).

TypeBroad incumbent
Description

Large biopharmaceutical company commercializing EYLEA (aflibercept), the market-leading anti-VEGF therapy for wet AMD and DME. Comparable as the dominant incumbent Surrozen's pipeline aims to disrupt in retinal disease.

TypeBroad incumbent
Description

Major biopharmaceutical company marketing Lucentis and Vabysmo for wet AMD and DME. Comparable as an entrenched anti-VEGF incumbent whose products define the current standard of care Surrozen's candidates aim to improve upon.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors19 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Surrozen

Ophthalmic Biopharmaceutical Therapeuticssurrozen.com

Surrozen is a clinical-stage biopharmaceutical company that engineers multivalent antibodies to selectively activate Wnt signaling for the treatment of retinal vascular diseases, with a pipeline of drug candidates for wet AMD, diabetic macular edema, and uveitic macular edema.

What Surrozen does

Surrozen is a clinical-stage biopharmaceutical company developing antibody therapeutics that selectively activate the Wnt signaling pathway to drive tissue repair and vascular regeneration in the eye. Founded in 2016 in South San Francisco and publicly listed on Nasdaq under ticker SRZN, the company operates with 11-50 employees and is led by CEO Craig Parker. Its proprietary SWAP (Surrozen Wnt Signal Activating Proteins) platform engineers multivalent antibodies capable of combining Wnt pathway activation with modulation of other disease drivers such as VEGF and IL-6, addressing ophthalmic indications with high unmet need including wet age-related macular degeneration, diabetic macular edema, and uveitic macular edema.

The pipeline comprises SZN-413 (a FZD4-targeting bispecific Wnt agonist licensed to Boehringer Ingelheim, with a milestone achieved in 2025), SZN-8141 (a FZD4/VEGF bifunctional antibody with IND filing expected in H2 2026), SZN-8143 (a FZD4/VEGF/IL-6 trifunctional antibody with IND expected in 2027), and SZN-113 (a multi-Wnt-receptor agonist for corneal and retinal degenerative conditions). The company discontinued its SZN-043 liver disease candidate in March 2025 to focus exclusively on ophthalmology.

The business model is a hybrid of out-licensing (SZN-413 to Boehringer Ingelheim) and future direct commercialization of wholly-owned ophthalmology assets. With no commercial products today, Surrozen generates de minimis collaboration revenue (Q4 2025: $0.53M) and is funded by a $175M oversubscribed private placement completed in March 2025, alongside public equity capital. Target customers are ultimately retinal specialists and their patients, with the company signaling a traditional biotech GTM of clinical development, analyst/investor engagement, and strategic licensing partnerships rather than direct sales infrastructure.

Surrozen firmographics

Firmographics
Name
Surrozen
Legal name
Surrozen, Inc.
Website
https://surrozen.com
Company type
Public
Founded year
2016
Operating status
Operating
Headcount range
51–100 employees
Short description
Surrozen is a clinical-stage biopharmaceutical company that engineers multivalent antibodies to selectively activate Wnt signaling for the treatment of retinal vascular diseases, with a pipeline of drug candidates for wet AMD, diabetic macular edema, and uveitic macular edema.
Ownership category
akta.pro rank

Surrozen industry classification

Industry
Product category
Ophthalmic Biopharmaceutical Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIACAK
Ophthalmology Specialty Pharmaceuticals

Keywords

  • Wnt pathway therapeutics
  • Ophthalmic antibody therapeutics
  • Retinal disease pipeline
  • Biopharmaceutical drug development
  • Multifunctional antibody engineering

Where Surrozen is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Markets served

Surrozen business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Others

Revenue model

  1. Pharmaceutical Product Revenue: Surrozen is a clinical-stage biopharmaceutical company with no current product revenue. The company is developing drug candidates targeting ophthalmic diseases and plans to commercialize pipeline assets upon regulatory approval. Future revenue will come from product sales, likely through licensing agreements or direct commercialization.
  2. Licensing and Collaboration Revenue: The company has licensing arrangements such as the Boehringer Ingelheim collaboration for SZN-413, which may generate milestone payments and potential royalties. The March 2025 $175M private placement discontinuing liver disease candidate SZN-043 indicates strategic focus on ophthalmology programs with potential partnership revenue.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Surrozen product offering

Product offering

Core offering

Surrozen is a clinical-stage biopharmaceutical company that develops multifunctional antibody therapeutics targeting the Wnt signaling pathway for ophthalmic diseases. Using its proprietary SWAP platform, Surrozen engineers multivalent antibodies that selectively activate Wnt signaling in ocular tissues to treat retinal vascular diseases including wet AMD, diabetic macular edema, and uveitic macular edema. The pipeline includes SZN-413 (licensed to Boehringer Ingelheim), SZN-8141, SZN-8143, and SZN-113.

Product overview

Surrozen is a clinical-stage biotechnology company that has developed a proprietary antibody-engineering platform to discover multifunctional antibodies targeting ophthalmic diseases. The company's pipeline includes multiple drug candidates: SZN-413 (FZD4 agonist, licensed to Boehringer Ingelheim), SZN-8141 (FZD4 + VEGF bifunctional antibody for wet AMD and DME), SZN-8143 (trifunctional antibody targeting FZD4, VEGF, and IL-6), and SZN-113 (agonist for FZD1, FZD2, FZD7 receptors). The underlying technology platform, SWAP (Surrozen Wnt Signal Activating Proteins), enables multivalent antibodies that potently and selectively activate Wnt signaling for tissue repair and regeneration.

Differentiator

Problem solved

Functional benefit

Brands

  • SWAPs (Surrozen Wnt Signal Activating Proteins): Proprietary multivalent antibodies that potently and selectively activate Wnt signaling in ocular tissues

Products and services

  • SZN-413

Quantifiable outcome

  • SZN-8141 peak probability-adjusted net sales projected at $895 million for diabetic macular edema and $614 million for neovascular age-related macular degeneration
  • +2 more outcomes

Companies that use Surrozen

Customer profile

Segments2 records

Ideal customer profiles2 records

Surrozen technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Surrozen partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Boehringer IngelheimcoreStrategic or Co-development Partner · 1 January 2025Strategic collaboration with Boehringer Ingelheim for SZN-413, a targeted bispecific Wnt agonist antibody for the treatment of retinal vascular diseases such as wet AMD and DME. Boehringer Ingelheim has licensed SZN-413 from Surrozen and is responsible for further development and potential commercialization. A milestone achievement by Boehringer Ingelheim for SZN-413 was reported in 2025.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Surrozen competitors and assessment

Company assessment

Direct peers

  • Kodiak Sciences: Clinical-stage biopharmaceutical company developing novel therapeutics for retinal vascular diseases including wet AMD and DME. Directly comparable as a small-cap ophthalmology biotech pursuing next-generation alternatives to anti-VEGF therapy with a pipeline of biologic candidates.
  • Adverum Biotechnologies: Clinical-stage gene therapy company focused on wet AMD and diabetic retinopathy. Directly comparable as a small-cap ophthalmology biotech developing novel mechanism therapies for retinal vascular disease.
  • Ocular Therapeutix: Clinical-stage biopharmaceutical company developing therapies for retinal diseases and other ophthalmic conditions including wet AMD. Comparable as a public ophthalmology-focused biotech with multiple pipeline assets in retinal disease.
  • Apellis Pharmaceuticals: Commercial-stage biopharmaceutical company with Syfovre and Empaveli for ophthalmology indications including geographic atrophy. Directly comparable as an ophthalmology-focused biotech, though more advanced commercially.
  • Outlook Therapeutics: Clinical-stage biopharmaceutical company developing ONS-5010/LYTENAVA, a candidate treatment for wet AMD. Directly comparable as a small ophthalmology-focused biotech targeting the wet AMD market.
  • Annexon Biosciences: Clinical-stage biopharmaceutical company developing complement-mediated therapies for ophthalmology (geographic atrophy) and neurology. Comparable as a clinical-stage biotech with novel mechanism ophthalmology programs.

Emerging players

  • REGENXBIO: Clinical-stage gene therapy company with ABBV-RGX-314 for wet AMD in collaboration with AbbVie. Comparable for its ophthalmology pipeline and partnership-driven business model, though using a different modality (gene therapy).
  • Lineage Cell Therapeutics: Clinical-stage cell therapy company with OPC1 for retinal indications. Comparable as a small-cap biotech developing novel regenerative therapies for ophthalmology, with a different modality (cell therapy).

Broad incumbents

  • Regeneron Pharmaceuticals: Large biopharmaceutical company commercializing EYLEA (aflibercept), the market-leading anti-VEGF therapy for wet AMD and DME. Comparable as the dominant incumbent Surrozen's pipeline aims to disrupt in retinal disease.
  • Genentech (Roche): Major biopharmaceutical company marketing Lucentis and Vabysmo for wet AMD and DME. Comparable as an entrenched anti-VEGF incumbent whose products define the current standard of care Surrozen's candidates aim to improve upon.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Surrozen social profiles

Digital presence

Surrozen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Surrozen leadership team

Management profile

Number of profiles

Profiles7 records

Surrozen funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Surrozen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Surrozen

What does Surrozen do?

Surrozen is a clinical-stage biopharmaceutical company that develops multifunctional antibody therapeutics targeting the Wnt signaling pathway for ophthalmic diseases. Using its proprietary SWAP platform, Surrozen engineers multivalent antibodies that selectively activate Wnt signaling in ocular tissues to treat retinal vascular diseases including wet AMD, diabetic macular edema, and uveitic macular edema. The pipeline includes SZN-413 (licensed to Boehringer Ingelheim), SZN-8141, SZN-8143, and SZN-113.

Is Surrozen a public or private company?

Surrozen is a public company. It is classified as public and is currently operating.

When was Surrozen founded?

Surrozen was founded in 2016. It employs 51 to 100 people.

Where is Surrozen based?

Surrozen is headquartered in South San Francisco, United States, in the North America region.

How does Surrozen make money?

Two revenue lines are on record. Pharmaceutical Product Revenue is the primary driver. The others are licensing and Collaboration Revenue.

Who are Surrozen's main competitors?

Direct peers on record are Kodiak Sciences, Adverum Biotechnologies, Ocular Therapeutix, Apellis Pharmaceuticals, Outlook Therapeutics and Annexon Biosciences. Emerging players are REGENXBIO and Lineage Cell Therapeutics. Broad incumbents are Regeneron Pharmaceuticals and Genentech (Roche).

Does Surrozen have an API?

No public API is recorded for Surrozen.

What industry is Surrozen in?

Surrozen's product category is Ophthalmic Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Defense WorldHead to Head Contrast: Surrozen (NASDAQ:SRZN) vs. Swedish Orphan Biovitrum (OTCMKTS:BIOVF)Swedish Orphan Biovitrum beats Surrozen on 8 of 13 factors, including revenue and earnings. Surrozen trades at a lower P/E ratio and has a higher analyst price target, suggesting more upside. Both are biotech firms, but Sobi has stronger profitability and institutional ownership.Business & FinancialSurrozen Announces Pricing Of $60 Million Underwritten Offering Of Common StockSurrozen announced a $60 million underwritten offering of common stock, with participation from Access Biotechnology, Boxer Capital Management, and others. Morgan Stanley, Guggenheim Securities, and Cantor are joint book-runners. The offering is made under a shelf registration statement filed with the SEC.Stock TitanSurrozen to Present at Guggenheim Healthcare ConferenceSurrozen management will present at Guggenheim's 3rd Annual Healthcare Innovation Conference on November 10, 2026, in a fireside chat. The company, a biotech developing Wnt-based therapeutics for sight-threatening eye conditions, will host a live webcast with a replay archived for 30 days.Business & FinancialSurrozen To Present At Upcoming Healthcare Investor ConferenceSurrozen will present at Guggenheim's 3rd Annual Healthcare Innovation Conference on November 10, 2026, at 1:30 PM Pacific Time. The biotech company develops Wnt-based therapeutics for sight-threatening ophthalmic conditions, with forward-looking statements covering its cash runway into 2029 and clinical development plans.American Banking and Market NewsSurrozen (SRZN) Expected to Post Quarterly Earnings on FridaySurrozen is expected to report Q3 2026 earnings on Friday, November 6th, with analysts projecting a loss of $1.1039 per share and revenue of $0.47 million. The company's stock opened at $29.46, and analysts have a consensus rating of Moderate Buy with an average price target of $48.33.Business & FinancialDiabetic Retinopathy Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead The Charge In Pioneering New Treatments DelveinsightDelveInsight's report on the diabetic retinopathy pipeline covers 50+ companies and 55+ pipeline drugs, including Phase 3 data for Kodiak Sciences' Zenkuda and FDA clearance for Surrozen's SZN-8141. The report assesses therapies by stage, route, and molecule type, highlighting unmet needs and future perspectives.MarketBeatSurrozen, Inc. $SRZN Shares Sold by Regents of The University of CaliforniaRegents of the University of California sold 83,333 Surrozen shares in Q3, trimming its stake by 38.5% to 133,207 shares. The stock opened at $29.53, with analysts giving a Moderate Buy rating and a $48.33 price target.Quiver QuantitativeSurrozen Closes $95.1 Million Private Placement Tranche | SRZNW Stock NewsSurrozen closed its second and final tranche of the March 2025 private placement, generating about $95.1 million in gross proceeds. The closing followed FDA clearance of the IND for SZN-8141 on October 2, 2026, and the company expects cash to fund operations into 2029.Markets DailySurrozen, Inc. (SRZN) – What Are Brokerages Thinking About This Stock?Surrozen shares received a consensus 'Moderate Buy' rating from seven firms, with an average 12-month price target of $48.33. The company reported a quarterly loss of $0.41 per share, beating estimates, and revenue of $5.00 million. Major shareholder Tcg Crossover Gp Ii sold 325,000 shares at $21.25.American Banking and Market NewsWhitehawk Therapeutics (NASDAQ:WHWK) and Surrozen (NASDAQ:SRZN) Critical ComparisonWhitehawk Therapeutics and Surrozen are compared on valuation, risk, ownership, and analyst ratings. Whitehawk has higher revenue and earnings, a lower P/E ratio, and a stronger consensus rating with higher upside. It beats Surrozen on 10 of 14 factors.